US Patent

US8829054 — Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container

Formulation · Assigned to HQ Specialty Pharma Corp · Expires 2033-03-15 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a ready-to-use injectable pharmaceutical composition of Esmolol hydrochloride in a modified flexible plastic container that can be heat-sterilized.

USPTO Abstract

A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol. The ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is capable of being stored in a modified flexible plastic container that may be heat-sterilized without deformation and/or without having the integrity of the closure system being compromised. A method for the manufacture of the ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US8829054
Jurisdiction
US
Classification
Formulation
Expires
2033-03-15
Drug substance claim
No
Drug product claim
Yes
Assignee
HQ Specialty Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.